BioRegenerative Sciences, Inc. to Present S2RM® Stem Cell Technology at 3rd International Conference on Tissue Engineering

San Diego, CA, June 13, 2013 --(PR.com)-- BioRegenerative Sciences, Inc. (BRS), a privately owned stem cell therapeutics corporation headquartered in San Diego, CA, USA, announced that Dr. Greg Maguire, CEO and Co-Founder, has been invited to present a lecture entitled, “Stem cell released molecules and exosomes in tissue engineering” at the 3rd International Conference on Tissue Engineering in Leiria, Portugal. Dr. Maguire explained that, “S2RM® stem cell technology has been shown to rebuild tissue, reduce pain and inflammation, and modulate immune function. Using the correct combinations of stem cell types, stimulating the cells in different ways, and adjusting the ratios of molecules, we can produce specific types of the S2RM to treat different diseases or traumatic conditions. Up to 80% of the therapeutic value of stem cells is through the release of molecules as opposed to the benefit derived from the differentiation of the stem cell. Further, if processed correctly, the stem cells release a naturally occurring nanoparticle, called an exosome, that packages and protects the molecules, and then delivers the molecules to target tissue.” Dr. Maguire added, S2RM® is a biomimetic that uses the molecules released from multiple stem cell types in a patent pending process to develop therapeutics and medical procedures that mimic mother nature’s healing processes. When the body is diseased or traumatized, multiple stem cell types are usually recruited to the affected area where the stem cells release a combination of molecules to orchestrate the healing process.”

President and Co-Founder Peter Friedman explained that “S2RM® technology, incorporating the naturally occurring exosomes, provides a powerful delivery and protection technology so that the molecules can pass through barrier tissues such as the skin’s stratum corneum. Moreover, the exosomes are immuno-privileged and can pass through the blood-brain barrier.” Dr. Andrew Maniotis, Division Head of the Cancer Biology Program at BRS explained the new exosome technology developed at BRS, “we developed a new process to enrich and collect exosomes from stem cells of various tissues, including the gut’s immune system that should prove to be very therapeutic for a number of indications.”

The S2RM® technology is explained in two recently published peer reviewed journal articles: 1. Maguire, G and Friedman, P. (2013) The systems biology of stem cell released molecules-based therapeutics. ISRN Stem Cells V 2013:784541, and 2. Maguire, G. et al. (2013) Stem cell released molecules and exosomes in tissue engineering. Procedia Engineering 59:270-278.

BioRegenerative Sciences, Inc. currently has fifteen patent pending products on the market and is further developing a portfolio of therapeutic and cosmeceutical products, and services based on BRS’s core stem cell-based S2RM® Technology. For more information, please email: gmaguire@bioregenerativesciences.com, or call BRS at 858. 521.9203.